Healthcare Utilization and Cost Burden of Porphyria in Commercially Insured Adults in the United States

Mohamed I. Elsaid (), You Li (), Carolyn Catalano (), Carlos D. Minacapelli (), Kapil Gupta () and Vinod K. Rustgi ()
Additional contact information
Mohamed I. Elsaid: Rutgers Robert Wood Johnson Medical School
You Li: Rutgers Robert Wood Johnson Medical School
Carolyn Catalano: Rutgers Robert Wood Johnson Medical School
Carlos D. Minacapelli: Rutgers Robert Wood Johnson Medical School
Kapil Gupta: Rutgers Robert Wood Johnson Medical School
Vinod K. Rustgi: Rutgers Robert Wood Johnson Medical School

PharmacoEconomics - Open, 2021, vol. 5, issue 1, No 10, 89-100

Abstract: Abstract Objectives The healthcare burden associated with porphyria remains unevaluated despite the associated increased risks of morbidity and mortality. We aimed to assess the healthcare utilization and cost burdens of porphyria in the United States (US) using real-world claims data. Methods We performed a case–control analysis of adults in the Truven Health MarketScan® Commercial Claims database (2010–2015). Using propensity scores, 2788 porphyria cases were matched 1:1 to porphyria-free controls with chronic liver disease. Total and service-specific parameters were quantified for the 12 months before porphyria diagnosis versus the 12 months after diagnosis and over the 12 months following a randomly selected date for controls. Wilcoxon signed rank tests and McNemar tests were used to examine incremental differences in burden between cases and controls. Adjusted multivariable generalized linear regression models were used to compare healthcare burdens for cases versus controls. Results Relative to the 12 months before porphyria diagnosis, the following 12 months had more claims per patient (35.94 vs 39.67; p

Date: 2021
References: View complete reference list from CitEc
Citations:

Downloads: (external link)
http://link.springer.com/10.1007/s41669-020-00229-4 Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:pharmo:v:5:y:2021:i:1:d:10.1007_s41669-020-00229-4

Ordering information: This journal article can be ordered from
http://www.springer.com/adis/journal/41669

DOI: 10.1007/s41669-020-00229-4

Access Statistics for this article

PharmacoEconomics - Open is currently edited by Timothy Wrightson and Christopher Carswell

More articles in PharmacoEconomics - Open from Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().